-
In addition to identifying several patient risk factors for contamination of blood culture specimens, the authors also highlighted various adverse clinical and financial adverse effects.
-
Cholinesterase inhibitors are one of the few drug classes approved by the FDA to treat patients with Alzheimer’s disease. This study shows a long-term benefit in slowing the decline of cognition, but it is unclear if there is any benefit in quality of life.
-
Disparate public health messaging from political officials, news media, and online outlets has occurred throughout the COVID-19 pandemic in the United States. Some have wanted to ascribe lower rates of compliance with public health guidance to political affiliation.
-
Researchers found many survivors of COVID-19 exhibited significant loss of health six months after their acute illness, with greater risk associated with severity of the acute infection.
-
An analysis of the utility of implanted loop recorders to detect subclinical atrial fibrillation in high-risk individuals showed that among common arrhythmia-compatible symptoms, only palpitation was predictive of discovering episodes of atrial fibrillation.
-
Considering the prevalence of sexually transmitted diseases (STDs) in adolescents and young adults, should pediatric EDs screen for STDs when these patients present to the ED? From a cost-effectiveness standpoint, the answer is yes, according to a team of researchers who examined this issue recently.
-
While STD clinics and primary care clinicians detect and treat many of these cases, there is no question EDs play an outsize role in caring for patients with STDs, particularly among disadvantaged populations. However, evidence suggests many EDs are not using all the tools at their disposal to facilitate treatment and curb transmission.
-
Right after the FDA issued an emergency use authorization for one drug, feds pressed pause on distributing another.
-
How would one interpret the ECG in the figure, obtained in the ED from a middle-aged man with new chest pain?
-
The FDA has approved a new, but controversial, treatment for Alzheimer’s disease.
